Pharmaceutical industry news
Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.
36,672 stories, page 166 of 612
🌍Researchdoi.orgTier 1 · Research record
Impact of Response to Hypomethylating Agent‐Based Therapy on Survival Outcomes in the Context of Baseline Clinical‐Molecular Risk and Transplant Status in Patients With Higher‐Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)
CrossrefOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry
NCT07730489: A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
Study type: INTERVENTIONAL. Phase: PHASE3.
ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry
NCT07506863: A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Study type: INTERVENTIONAL. Phase: PHASE3.
ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry
NCT05500092: An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Study type: INTERVENTIONAL. Phase: PHASE2.
ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry
NCT05314998: Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
Study type: INTERVENTIONAL. Phase: PHASE3.
ClinicalTrials.govOriginal source






